Heat-induced reformulation of amphotericin B-deoxycholate favours drug uptake by the macrophage-like cell line J774

Journal of Antimicrobial Chemotherapy

Volumn 52, Issue 6, 2003, Pages 904-910

  Chéron, Monique ^a   Petit, Caroline ^a   Bolard, Jacques ^a   Gaboriau, François ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Amphotericin B; Lipoproteins; Macrophages; Serum; Toxicity

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; AMPHOTERICIN B DEOXYCHOLATE; ANTILEISHMANIAL AGENT; LACTATE DEHYDROGENASE; PLASMA PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LINE; CELL VIABILITY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG UPTAKE; ENZYME RELEASE; FETAL CALF SERUM; HEATING; IN VITRO STUDY; KIDNEY EPITHELIUM; LEISHMANIASIS; MACROPHAGE; MEMBRANE DAMAGE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; SPECTROPHOTOMETRY;

ALGORITHMS; AMPHOTERICIN B; ANIMALS; ANTIBIOTICS, ANTIFUNGAL; CELL LINE; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DEOXYCHOLIC ACID; DRUG COMBINATIONS; HEAT; L-LACTATE DEHYDROGENASE; LIPOPROTEINS, LDL; LLC-PK1 CELLS; MACROPHAGES; MICE; SWINE; TETRAZOLIUM SALTS; THIAZOLES;

EID: 0346258302     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg455     Document Type: Article

References (23)

1. Hartsel, S. & Bolard, J. (1996). Amphotericin B: new life for an old drug. Trends in Pharmacological Sciences 17, 445-9.
2. Dupont, B. (2002). Overview of the lipid formulations of amphotericin B. Journal of Antimicrobial Chemotherapy 49, 31-6.
3. Wongberinger, A., Jacobs, R. A. & Guglielmo, B. J. (1998). Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clinical Infectious Diseases 27, 603-18.
4. Gaboriau, F., Chéron, M., Leroy, L. et al. (1997). Physicochemical properties of the heat-induced superaggregation of amphotericin B. Biophysical Chemistry 66, 1-12.
5. Gaboriau, F., Chéron, M., Petit, C. et al. (1997). Heat-induced superaggregation of amphotericin B reduces its in vitro toxicity: a new way to improve its therapeutic index. Antimicrobial Agents and Chemotherapy 41, 2345-51.
6. Petit, C., Chéron, M., Joly, V. et al. (1998). In-vivo therapeutic efficacy in experimental murine mycoses of a new formulation of deoxycholate-amphotericin B obtained by mild heating. Journal of Antimicrobial Chemotherapy 42, 779-85.
7. Petit, C., Yardley, V., Gaboriau, F. et al. (1999). Activity of a heat-induced reformulation of amphotericin B deoxycholate (Fungizone) against Leishmania donovani. Antimicrobial Agents and Chemotherapy 43, 390-2.
8. Bau, P., Bolard, J. & Dupouy-Camet, J. (2003). Heated amphotericin to treat leishmaniasis. Lancet Infectious Diseases 3, 188.
9. van Etten, E. W., van Vianen, W., Roovers, P. et al. (2000). Mild heating of amphotericin B-desoxycholate: effects on ultrastructure, in vitro activity and toxicity, and therapeutic efficacy in severe candidiasis in leukopenic mice. Antimicrobial Agents and Chemotherapy 44, 1589-603.
10. Baas, B., Kindt, K., Scott, A. et al. (1999). Activity and kinetics of dissociation and transfer of amphotericin B from a novel delivery form. AAPS pharmSci 1, E10.
11. Hartsel, S. C., Baas, B., Bauer, E. et al. (2001). Heat-induced superaggregation of amphotericin B modifies its interaction with serum proteins and lipoproteins and stimulation of TNF-alpha. Journal of Pharmaceutical Sciences 90, 124-33.
12. Brajtburg, J. & Bolard, J. (1996). Carrier effects on biological activity of amphotericin B. Clinical Microbiology Reviews 9, 512-31.
13. Legrand, P., Vertut-Doï, A. & Bolard, J. (1996). Comparative internalization and recycling of different amphotericin B formulations by a macrophage-like cell line. Journal of Antimicrobial Chemotherapy 37, 519-33.
14. Krause, H. M. & Juliano, R. L. (1988). Interactions of liposome-incorporated amphotericin B with kidney epithelial cell cultures. Molecular Pharmacology 34, 296-7.
15. Wasan, K. M., Rosenblum, M. G., Cheung, L. et al. (1994). Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrobial Agents and Chemotherapy 38, 223-7.
16. Mosman, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods 65, 55-63.
17. Bergmeyer, H. U., Bernt, E. & Hess, B. (1963). Lactic dehydrogenase. In Methods of Enzymatic Analysis (Bergmeyer, H. U., Ed.), pp. 736-41. Academic Press, New York, NY, USA.
18. Ridente, Y., Aubard, J. & Bolard, J. (1999). Absence in amphotericin B-spiked human plasma of the free monomeric drug, as detected by SERS. FEBS Letters 446, 283-6.
19. Bekersky, I, Fielding, R. M., Dressler, D. E. et al. (2002). Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B cleoxycholate. Antimicrobial Agents and Chemotherapy 46, 834-40.
20. Brajtburg, J., Elberg, S., Bolard, J. et al. (1984). Interaction of plasma proteins and lipoproteins with amphotericin B. Journal of Infectious Diseases 149, 986-97.
21. Wasan, K. M., Brazeau, G. A. & Keyhani, A. (1993). Roles of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins. Antimicrobial Agents and Chemotherapy 37, 246-50.
22. Bhamra, R., Sa'ad, A., Bolcsak, L. E. et al. (1997). Behavior of amphotericin B lipid complex in plasma in vitro and in the circulation of rats. Antimicrobial Agents and Chemotherapy 41, 886-92.
23. Rogers, P. D., Barkers, K. S., Herring, V. et al. (2003). Heat-induced superaggregation of amphotericin B attenuates its ability to induce cytokine and chemokine production in the human monocytic cell line THP-1. Journal of Antimicrobial Chemotherapy 51, 405-8.